RxDoctor Payments DataLook up a doctor →

Todd Dunaway, MD

Neurology · Tulsa, OKNPI 1982624268

Payments from drug & device makers

$26,382in general payments, 2019–2025

Across 1,323 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • Novartis$2K
  • UCB, Inc.$2K
  • Genentech USA, Inc.$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $15K from 53 others

What the payments were for

  • Speaking & faculty fees$960%
  • Food & beverage$26,03299%
  • Education$2551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen114$2,306
Novartis139$2,166
UCB, Inc.79$2,002
Genentech USA, Inc.79$1,611
AbbVie(2 entities)136$1,578
Teva Pharmaceuticals USA, Inc.70$1,544
SK Life Science, Inc.52$1,372
CSL Behring66$1,133
AstraZeneca(2 entities)36$1,112
EMD Serono, Inc.49$1,081
Argenx US, Inc.27$901
TG Therapeutics, Inc.27$865
EDW Pharma, Inc.1$751
Amgen39$651
Sanofi38$647
Acadia Pharmaceuticals Inc20$567
Sunovion Pharmaceuticals Inc.43$439
Lundbeck LLC18$400
Tanabe Pharma America, Inc.16$307
Lilly USA, LLC18$302
Avanir Pharmaceuticals, Inc.19$293
Grifols USA, LLC13$291
Eisai Inc.14$279
Supernus Pharmaceuticals, Inc.32$269
Catalyst Pharmaceuticals, Inc.13$260
Johnson & Johnson9$253
Neurelis, Inc.11$217
Pfizer10$205
Acorda Therapeutics, Inc7$187
Sumitomo Pharma America, Inc.20$178
Medtronic(2 entities)6$169
Jazz Pharmaceuticals Inc.9$169
Amylyx Pharmaceuticals, Inc.8$163
Adamas Pharmaceuticals, Inc.8$159
Bristol Myers Squibb9$156
Avadel CNS Pharmaceuticals, LLC6$130
Impel Pharmaceuticals Inc.2$128
Biohaven Pharmaceutical Holding Company Ltd.9$117
Corium, LLC6$117
Livanova USA, Inc.4$104
Avion Pharmaceuticals6$101
Biohaven Pharmaceuticals, Inc.5$90
Amneal Pharmaceuticals LLC4$79
Arbor Pharmaceuticals, Inc.4$75
Takeda Pharmaceuticals U.S.A., Inc.2$57
Otsuka America Pharmaceutical, Inc.3$55
Kyowa Kirin, Inc.3$52
Scilex Pharmaceuticals Inc.2$40
E.r. Squibb & Sons, L.L.C.2$38
ITF Therapeutics LLC1$33
Harmony Biosciences LLC1$29
Alnylam Pharmaceuticals Inc.1$24
Vanda Pharmaceuticals Inc.1$24
MDD US Operations, LLC1$22
Akcea Therapeutics, Inc.1$21
Amicus Therapeutics, Inc.1$18
Sanofi-aventis U.S. LLC1$16
NS Pharma, Inc.1$15
Bioventus LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,382 in reported general payments places this provider in the 75th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$127,961
Medicare patients
482
Services billed
1,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5092$776,193
Gamunex-CImmune Globul G/Gly/Iga Avg 4688$661,057
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5023$522,745
EvrysdiRisdiplam15$405,834
Kesimpta PenOfatumumab23$257,553
CopaxoneGlatiramer Acetate29$217,539
Sodium Oxybate13$159,749
Rebif RebidoseInterferon Beta-1a/Albumin11$115,510
AptiomEslicarbazepine Acetate30$65,169
NuedextaDextromethorphan Hbr/Quinidine39$59,556
GlatopaGlatiramer Acetate15$51,790
Mycophenolate Mofetil264$46,381
Aimovig AutoinjectorErenumab-Aooe39$28,744
Glatiramer Acetate19$28,326
Pyridostigmine Bromide151$19,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$1,133$776,19392 claims
Grifols USA, LLCGamunex-C$291$661,05788 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$57$522,74523 claims
Genentech USA, Inc.Evrysdi$1,611$405,83415 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,544$217,53929 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide, Rytary$79$83,675430 claims
Sunovion Pharmaceuticals Inc.Aptiom$439$65,16930 claims
Avanir Pharmaceuticals, Inc.Nuedexta$293$59,55639 claims
PfizerEliquis, Dilantin$205$16,65424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →